Alligator Bioscience is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, with a focus on the CD40 receptor pathway. By activating the patient’s immune system directly within the tumor microenvironment, Alligator’s drug candidates aim to overcome immune suppression and drive potent anti-tumor responses.
The company’s lead asset, mitazalimab, is a CD40 agonist currently in preparation for Phase 3 development following encouraging results from the Phase 2 OPTIMIZE-1 trial in first-line metastatic pancreatic cancer. At 24-month follow-up, mitazalimab has demonstrated unprecedented survival outcomes, further supporting its therapeutic potential in this hard-to-treat disease.
Alligator’s pipeline includes both mono- and bispecific antibody programs, all designed to deliver localized immune activation and achieve an optimal balance of efficacy and safety.
Founded in 2001, Alligator is headquartered at Medicon Village in Lund, Sweden, and is listed on Nasdaq Stockholm under the ticker ATORX.